Collaboration can be extremely important when it comes to developing treatments, especially for rare disorders. Sharing information, technology, and expertise can lead to therapies that otherwise might not have seen the light of day. A new collaboration recently started to do just this, with the end goal of producing therapies for rare neurometabolic disorders.
About the Collaboration
Formed between Takeda Pharmaceuticals and Immusoft, this collaboration will focus on the development of cell therapies. Specifically, the two companies aim to create treatments for rare, inherited metabolic diseases with manifestations and/or complications of the central nervous system (CNS).
Through their agreement, Takeda and Immusoft will utilize Immusoft’s Immune System Programming (ISP™) technology platform. This innovative technology utilizes a patient’s B cells by modifying them to deliver therapies with encoded genes. The two companies have an interest in protein therapies that are able to cross the blood-brain barrier, as these treatments would address a severe unmet medical need.
The specific terms of the collaboration include:
- Takeda will provide Immusoft with a payment upfront, alongside research funding support.
- Options for Takeda to have exclusive licensing rights for preclinical programs.
- Immusoft holds eligibility for tiered royalties on any future products that arise from the collaboration.
- The responsibility of future development, both preclinical and clinical, and commercialization rests on Takeda.
- If all milestones are met, Immusoft may receive more than $900 million through milestone payments.
As patients with rare, neurometabolic disorders face an unmet medical need, this partnership is very exciting. Hopefully, it will provide more treatment options for a deserving patient population.
You can read more about this collaboration here.
